| Cell line name |
BxPC-3 XL-2 |
|---|
| Synonyms |
XL-2 |
|---|
| Accession |
CVCL_E4N9 |
|---|
| Resource Identification Initiative |
To cite this cell line use: BxPC-3 XL-2 (RRID:CVCL_E4N9) |
|---|
| Comments |
Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI_72317; Carbozantinib (Cometriq).
Derived from site: In situ; Pancreas; UBERON=UBERON_0001264. |
|---|
| Sequence variations |
- Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
- Gene deletion; HGNC; HGNC:6770; SMAD4; Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val487_Pro492delinsAla (c.1460_1474delGTGTAGGTGCTGTCA); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:6407; KRAS; None_reported; -; Zygosity=- (from parent cell line).
- Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line).
|
|---|
| Disease |
Pancreatic ductal adenocarcinoma (NCIt: C9120) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Hierarchy |
Parent: CVCL_E4N8 (BxPC-3 XL-1)
Children:
|
|---|
| Sex of cell |
Female |
|---|
| Age at sampling |
61Y |
|---|
| Category |
Cancer cell line |
|---|
| Publications | PubMed=23661005; DOI=10.1038/cddis.2013.158; PMCID=PMC3674365
Carina Hage, Vanessa Rausch, Nathalia A. Giese, Thomas Giese, Frank Schonsiegel, Sabrina Labsch, Clifford C. Nwaeburu, Juergen Mattern, Jury Gladkich, Ingrid Herr;
The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer.
Cell Death Dis. 4:e627.1-e627.10(2013) |
|---|
| Entry history |
|---|
| Entry creation | 19-Dec-2024 |
|---|
| Last entry update | 19-Dec-2024 |
|---|
| Version number | 1 |
|---|
